Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia

Current Drug Safety

Volumn 5, Issue 2, 2010, Pages 171-181

  Cuker, Adam ^a   Chiang , Elaine Y ^a   Cines, Douglas B ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Eltrombopag; ITP; Romiplostim; Thrombopoiesis

Indexed keywords

AKR 501; ELTROMBOPAG; LGD 4665; NEUTRALIZING ANTIBODY; PLACEBO; ROMIPLOSTIM; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ARTHRALGIA; BACKACHE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; IMMUNE THROMBOCYTOPENIA; LEUKEMIA; LIMB PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; MONOCLONAL IMMUNOGLOBULINEMIA; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 77950845568     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610790936196     Document Type: Review

References (82)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
3. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106: 2244-2251
4. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesisstimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681
5. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a doubleblind randomised controlled trial. Lancet 2008; 371: 395-403.
6. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247
7. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebocontrolled trial. Lancet 2009; 373: 641-648
8. Cheng G, Saleh MN, Bussel JB, et al. Oral eltrombopag for the longterm treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III double-blind, placebo-controlled study (RAISE). Blood 2008; 112: abstract 400.
9. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171
10. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616
11. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-912
12. Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl 2008; 80: 9-18.
13. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-1124
14. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-568
15. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiologic regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-11108
16. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a panhematopoietic cytokine. Cytokine Growth Factor Rev 2002; 13: 61-73.
17. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-2161
18. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet production. Blood 1996; 87: 4068-4071
19. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996; 76: 156-160 (Pubitemid 26285242)
20. Chang M, Qian JX, Lee SM, et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood 1999; 93: 2515-2524
21. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-706
22. Kuter DJ. The physiology of platelet production. Stem Cells 1996; 14(1): 88-101.
23. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic anutoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40.
24. Isaka Y, Kambayashi J, Kimura K, et al. Platelet production, clearance and distribution in patients with idiopathic thrombocytopenic purpura. Thromb Res 1990; 60: 121-131
25. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103: 500-506
26. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364-1369
27. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895
28. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25: 52-60.
29. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725
30. AMG 531 Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura [online]. Available from URL:http://clinicaltrials.gov/ ct2/show/NCT00415532 [Accessed 2009 January 8]
31. Erickson-Miller CL, DeLorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424-430
32. Promacta prescribing information [online]. Available from URL: http://www.promactacares.com/prescribing-information.pdf [Accessed 2009 January 14]
33. Bussel JB, Cheng G, Saleh MN, et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood 2008; 112: abstract 3432.
34. Fogarty PF, Bussel JB, Cheng G, et al. Oral eltrombopag treatment reduces the need for concomitant medications in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008; 112: abstract 3424.
35. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006; 108: abstract 477.
36. Dziewanowska ZE, Kapil RP, Zhang JK, et al. Clinical characterization of a novel oral thrombopoietin mimetic LGD-4665 in healthy volunteers demonstrating safe and sustained increases in platelet counts with flexible dosing choices for phase II trials. Blood 2008; abstract 3406.
37. Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00441090 [Accessed 2009 January 8]
38. Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00621894 [Accessed 2009 January 8]
39. Liem-Moolenaar M, Cerneus D, Molloy C, et al. Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin Pharmacol Ther 2008; 84: 481-487
40. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68: 210-214
41. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100: 728-730
42. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126: 673-681
43. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404-409
44. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebocontrolled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgastrim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118-3128
45. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000; 18: 2852-2861
46. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98: 1346-1351
47. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98: 1339-1345
48. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
49. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99: 2599-2602
50. Nplate prescribing information [online]. Available from URL: http://www.nplatenexus.com/pdfs/misc/nplate-pi.pdf [Accessed 2009 January 14]
51. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: physiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139: 351-362
52. Mufti G, Bagg A, Hasserjian R, et al. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood 2006; 108: abstract 3982.
53. Bauermeister DE. Quantitation of bone marrow reticulin - a normal change. Am J Clin Pathol 1971; 56: 24-31.
54. Beckman EN, Brown AW Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 1990; 114: 1241-1243
55. Kimura A, Katoh O, Hyodo H, Kuramoto A. Transforming growthfactor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989; 72: 486-491
56. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible inplications in myelofibrosis. Blood 1990; 75: 1540-1548
57. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87: 5006-5015
58. Yanagida M, Ide Y, Toriyama M, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997; 99: 739-745
59. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86: 4025-4033
60. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002; 117: 844-850
61. Kuter DJ, Mufti G, Bain B, Hasserjian R, Rutstein M. Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic immune thrombocytopenic purpura (ITP). Blood 2008; 112: abstract 3416.
62. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132
63. GlaxoSmithKline Data on File, 2008. EM2008/00007/00
64. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205-213
65. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2005; 84: 411-415
66. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol 2004; 76: 143-147
67. Hassn AM, Al-Fallouji MA, Ouf TI, Saad R. Portal vein thrombosis following splenectomy. Br J Surg 2000; 87: 362-373
68. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-1844 (Pubitemid 26068898)
69. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-521 (Pubitemid 26240383)
70. Peng J, Friese P, Wolf RF, et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996; 87: 4158-4163
71. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741
72. Liebman H, Henry D, Lefrere F, et al. Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP). Blood 2008; 112: abstract 3415.
73. Bussel JB, Psaila B, Saleh MN, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008; 112: abstract 3431.
74. Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006; 42: 3028-3033
75. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98: 1321-1330
76. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55: 3509-3512
77. Archimbaud E, Ottoman OG, Yin JA, et al. A randomized, doubleblind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94: 3694-3701
78. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebocontrolled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95: 2530-2535
79. LENS - Long-Term Eltrombopag Observational Study [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00643929 [Accessed 2009 January 14]
80. Promacta FDA Oncologic Drug Advisory Committee Briefing Document [online]. Available from URL:http://www.fda.gov/ohrms/dockets/AC/08/briefing/ 2008-4366b1-02-GSK.pdf [Accessed 2009 February 16]
81. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-2236
82. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554